Binny Mills Limited (BOM:535620)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-	-127.06	-145.01	-108.78	-112.33	222.53
Depreciation & Amortization	-	0.32	0.16	0.17	0.11	0.17
Provision & Write-off of Bad Debts	-	-	-	-	-	0.01
Other Operating Activities	-	-35.05	-38.98	-37.32	-29.09	-366.46
Change in Accounts Receivable	-	-0.3	0.85	7.72	-2.85	-2.01
Change in Inventory	-	3.02	0.28	1.26	-1.29	-0.82
Change in Accounts Payable	-	-1.92	-1.75	-6.79	4.33	4.64
Change in Other Net Operating Assets	-	424.33	215.51	77.08	127.19	125.85
Operating Cash Flow	-	263.35	31.06	-66.66	-13.92	-16.09
Operating Cash Flow Growth	-	747.97%	-	-	-	-
Capital Expenditures	-	-	-0.06	-0.17	-1.56	-1.88
Sale (Purchase) of Real Estate	-	-34.45	-	-	-	-
Investment in Securities	-	-12.91	-18	33.54	-13.28	-20.26
Other Investing Activities	-	29.68	28.27	35.24	31.7	32.82
Investing Cash Flow	-	-17.68	10.22	68.61	16.86	10.68
Long-Term Debt Issued	-	50	-	-	-	-
Net Debt Issued (Repaid)	-	50	-	-	-	-
Repurchase of Common Stock	-	-340	-	-	-	-
Financing Cash Flow	-	-290	-	-	-	-
Miscellaneous Cash Flow Adjustments	-	-	-	-	-	0
Net Cash Flow	-	-44.33	41.27	1.95	2.94	-5.41
Free Cash Flow	-	263.35	31	-66.83	-15.48	-17.97
Free Cash Flow Growth	-	749.47%	-	-	-	-
Free Cash Flow Margin	-	416.57%	44.45%	-88.37%	-20.11%	-29.22%
Free Cash Flow Per Share	-	101.94	9.72	-20.96	-4.86	-5.64
Cash Income Tax Paid	-	5.28	4.59	7.67	6.48	5.83
Levered Free Cash Flow	-	317.81	70.16	60.58	93.88	-272.57
Unlevered Free Cash Flow	-	396.96	149.31	139.73	173.03	-193.42
Change in Net Working Capital	-399.85	-402.68	-169.76	-128.02	-160.73	204.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.